听

91探花 is excited to announce the winners of the 2026 HealthTech44 campaign, celebrating the most exciting and innovative businesses in health and medical technology this year.

Founded in 2016, 91探花 is the UK鈥檚 best-known and fastest-growing startup and tech news site. This听is where decision-makers, investors and startups of all sizes and nature come to find out the latest developments and trends within the industry.

听

See The List

听

Top 44 鈥� See Here >>

Top 40 鈥� See Here >>

Top 30 鈥� See Here >>

Top 20 鈥� See Here >>

Top 10 鈥撎�See Here >>

Who Ranked Number 1? 鈥撎�See Here听>>

听

Feedback From The Judges

One of the most encouraging aspects of judging this year鈥檚 HealthTech44 competition was seeing how many founders were thinking beyond the technology itself. The strongest entries combined innovative technology with a clear understanding of the clinical problem they were solving and a credible pathway to bringing that solution into practice. That combination of innovation, evidence and a clear route to adoption made this an exceptionally strong field and was a reminder of just how much high-quality innovation is taking place across the sector. Congratulations to everyone who took part, and particularly to this year鈥檚 winners.

Head Judge 2026

Dr. Stuart Grant, Founder of

听

Judging this field reinforced how quickly healthtech is moving from point solutions toward trusted clinical infrastructure. The strongest entries did more than present an interesting idea: they addressed a meaningful care or workflow problem, showed evidence of execution, and designed around the realities of clinicians, patients, regulation, and deployment. I was particularly drawn to companies combining clinical usefulness with measurable traction, explainable AI, strong data foundations, or devices capable of improving access outside traditional care settings.

I deliberately did not rank companies based only on size, valuation, or fundraising. Several early-stage teams scored well because the problem was urgent, the founder insight was authentic, and the pathway to validation was credible. The main gap across weaker entries was not ambition, but proof鈥攃lear outcomes, regulatory strategy, differentiation, and evidence that the solution can work consistently in real healthcare environments.

Jeremy Lawson, Founder and CEO of Salynt Inc.

听

As an independent virtual CISO with a background in risk management, cybersecurity, and regulatory compliance, I prefer facts over marketing claims. For 91探花鈥檚 HealthTech44 2026, I ranked the submissions on five evidence-based dimensions: stated security maturity, AI claim substantiation, clinical validity, patient impact, and the team鈥檚 credibility. Companies that scored higher had provided named certifications, published benchmarks, regulatory clearance, quantified outcomes, and experienced clinical leaders named in their submission. By comparison, entries with visible AI instructions, placeholder content, or contradictory claims were disqualified, and submissions that were primarily unsubstantiated product marketing ranked poorly with me.

Kayne McGladrey, Independent Virtual CISO

听

The list of startups are amongst the top health tech companies in the world tackling the most challenging health problems with their impact able to improve healthcare outcomes around the world. With the current theme of AI helping to deliver great outcomes, I am glad to see many healthtech companies utilising and being AI-first.

Samuel Okwuada, Founder and CEO of Remedial Health

听

Judging this year鈥檚 HealthTech competition was an inspiring experience. The quality of the submissions reflected the incredible innovation happening across the healthcare sector, with companies tackling real-world challenges through technology. From advancements in remote patient monitoring to AI-driven diagnostics and neurological care, these solutions demonstrated both technical excellence and a clear understanding of the needs of patients and healthcare professionals. What stood out most was the focus on creating accessible, scalable technologies with the potential to make a meaningful impact. It was encouraging to see such a high standard of innovation, and I look forward to seeing how these companies continue to shape the future of healthcare.听

Laliq Schuman, Reporter and SEO Executive at 91探花听

听

Thank You To Our Judges

听

Head Judge 2026

Dr. Stuart Grant, Founder of

Dr. Stuart Grant is the Founder of Archetype MedTech, where he provides product development leadership to founders, investors, and MedTech companies, bringing innovative medical technologies to market.

Alongside Archetype, Stuart is Co-Founder of C-True Surgical, Product Development Leadership Advisor to the Science and Engineering Health Technologies Alliance (SEHTA) and a Product Development Mentor with the NHS Clinical Entrepreneur Programme. His work spans the UK, Europe, the US and APAC, including Australia, China, and India.

Before founding Archetype, Stuart spent 25 years with Johnson & Johnson MedTech, where he established and led the company鈥檚 Shanghai R&D Centre of Excellence. He is a Chartered Engineer, a Fellow of the Institution of Mechanical Engineers, holds a PhD in Medical Device Technology and Innovation, is a named inventor on multiple US medical device patents and is a regular speaker, mentor and contributor across the global MedTech sector.

Read more about Dr. Stuart Grant and what he鈥檚 looking out for in HealthTech44 entrants here.

听

Aline G贸mez-Acebo Finat, CEO at ENIAX

Aline Gomez-Acebo Finat is a prominent tech operator, angel investor, and ecosystem builder specializing in deep tech, digital health, and venture capital. As the CEO of ENIAX, she scales a healthtech platform utilizing machine learning and natural language processing to manage data for nearly 100 million patients across 8 countries.

Committed to bridging the venture funding gap, she is also the Co-Founder of Calafia Iberia, the region鈥檚 first women-led angel investment syndicate. An Adjunct Professor at IE Business School with executive credentials from MIT, Stanford, and Harvard, Aline has received numerous awards like Top 100 Female Leader and EPIC award for her sustainability efforts in business.

听

Jeremy Lawson, Founder and CEO of Salynt Inc.

Jeremy Lawson is the Founder and CEO of Salynt Inc., a healthcare AI company developing advanced neuroimaging and clinical decision-support technologies that help clinicians better understand and treat complex neurological conditions. With over a decade of experience in artificial intelligence, data science, and technology innovation across the Department of Defense and Intelligence Community, he understands the intersection of healthcare, technology, and commercialization. Jeremy holds a Master鈥檚 in Data Science from The George Washington University and a Bachelor鈥檚 in Mathematics from Jackson State University.

Beyond his professional work, Jeremy is committed to mentorship, education, and community impact. He is a member of The National Alliance for Doctoral Studies in the Mathematical Sciences and previously served as President of the Maryland Black Caucus Foundation and Vice President of the International Black Firefighters Museum. He is passionate about empowering the next generation of innovators while advancing technologies that improve patient outcomes and clinical decision-making.

Jeremy enjoys cooking, playing the piano, traveling, and watching football in his spare time.

听

Kayne McGladrey, Independent Virtual CISO

Kayne McGladrey is an independent virtual CISO who helps SMBs and mid-market firms navigate compliance, AI regulation and cyber risk. Author of the upcoming book 鈥淐yber Risk is a Myth,鈥� and ranked number one globally for his cybersecurity and risk management expertise, Kayne bridges technical security with business outcomes.

听

Oren Hershkovitz, Chief Executive Officer and Enlivex

Oren Hershkovitz is the CEO at Enlivex (Nasdaq: ENLV), a quality longevity company advancing Allocetra, a clinical-stage immunotherapy targeting age-related osteoarthritis, alongside a prediction markets treasury strategy built around the RAIN protocol.

In 2025 the company reported $1.23 billion in net profit and received FDA clearance for a Phase 2b clinical trial in the same week. Oren is a pharmaceutical executive with over 20 years of experience leading clinical programs from early discovery through Phase III trials and has overseen more than $200 million in financing throughout his career. He holds a PhD in Immunology with distinction from Ben-Gurion University of the Negev.

Prior to joining Enlivex in 2019, Oren served as General Manager of OPKO Biologics, where he led the late-stage clinical development of Ngenla, a long-acting growth hormone co-developed with Pfizer that is now approved in more than 40 countries, including the United States, the European Union and Japan.

听

Samuel Okwuada, Founder and CEO of Remedial Health

Samuel Okwuada is the Founder and Chief Executive Officer of Remedial Health, a healthcare technology company focused on optimizing the pharmaceutical supply chain in Africa. Educated as a pharmacist with a Master鈥檚 degree in Pharmacy from the University of East Anglia, UK; he is also a self-taught software engineer who initially began writing code at age 14.

During his university studies, Okwuada established a track record as a serial entrepreneur by founding 3 distinct startup companies and successfully completing 2 corporate exits. Through his leadership at Remedial Health, he builds direct-to-retail distribution networks for medical and non-medical consumables to improve inventory affordability for independent pharmacies across the African continent. His platform directly addresses regional supply shortages and pricing inefficiencies within the traditional medical distribution model.

Okwuada remains focused on leveraging his dual expertise in software engineering and clinical pharmacy to modernize medicine access and healthcare logistics.

听

Laliq Schuman, Reporter and SEO Executive at 91探花

Laliq is an SEO Executive with experience writing optimised content for a wide range of clients. She specialises in creating SEO-driven blogs and on-site content that aligns with both search intent and brand voice. With a client base spanning multiple industries, Laliq brings a broad knowledge of tech and consumer-focused topics to her work. Her exposure to innovation-driven sectors has sparked a particular interest in how technology can support and improve healthcare.

The post Announced! 91探花’s HealthTech44 Winners 2026… appeared first on 91探花.

Co-Founder & CEO: Vasili Razhnou

Website:听

听

About MEDvidi

听

MEDvidi emerged from traditional offline clinics in San Francisco and Miami in 2019, transitioning to a custom telehealth platform in 2020. Co-founders Vasili Razhnou and Alex Kulitski combined healthcare operations and technology expertise to build a platform that connects patients with licensed therapists and prescribing clinicians in one coordinated care model 鈥� making high-quality, affordable mental health care accessible across the US for ADHD, anxiety, and depression.

The biggest problem in healthcare today is provider capacity. Millions of Americans cannot access mental health care. The reason is that psychiatrists are fully booked with routine follow-up visits and administrative tasks, leaving no capacity for new patients. MEDvidi built its AI directly around that bottleneck. The AI Chart Generator transcribes visits in real time, updating documentation every 60 seconds and cutting charting time by 10x.

The AI Chart Reviewer monitors 100 percent of clinical encounters for protocol adherence, reducing review time by 80 percent while handling ID verification, drug-seeking detection, and guideline compliance. An AI Receptionist manages rescheduling, gathers prescription-related updates from patients, and feeds everything back into clinical workflows. By removing that friction, MEDvidi enables clinicians to see up to 10 times more patients.

Unlike other AI health tools trained on non-specific medical data, MEDvidi AI is trained on 130,000 real psychiatric visits. It is purpose-built for psychiatric workflows, regulations, and controlled-substance requirements. It works as a clinical verification layer, grounded in evidence-based guidelines and a proprietary dataset of real historical visits, ensuring every prescription aligns with standards and providing regulators with transparent oversight. The AI does not make independent decisions. The view at MEDvidi is blunt: AI in medicine should solve bottlenecks in doctors鈥� workflows and make clinicians more capable, not replace them.

听

Want to find out what 91探花 can do for your business?

Contact us today.

The post 36. MEDvidi appeared first on 91探花.

Founder & CEO: Bilal Farooqi

Website:

听

听

About Sunny Health AI

听

Sunny Health AI is an AI-powered healthcare navigation platform that acts as a virtual healthcare concierge for employees and their families. The platform helps users understand their insurance benefits, locate in-network providers, book appointments, answer coverage questions, and coordinate follow-up care through conversational AI. Its primary customers are employers, particularly startups, looking to improve employee healthcare access while reducing HR workload and unnecessary healthcare spending.

听

Want to find out what 91探花 can do for your business?

Contact us today.

The post 40. Sunny Health AI appeared first on 91探花.

Co-Founders:听 Elena Ikonomovska (CEO) and Andrii Yasinetsky (CTO)

Website:听

听

听

About Diadia Health听

听

Diadia Health is a diagnostic reasoning platform built for clinicians who want AI they can verify, not just trust. Every AI tool that touches patient care makes claims. Diadia is the platform built to prove them: every clinical claim it generates is sorted into one of three tiers, Supported by Science, Plausible, or Unsupported, so clinicians see exactly why the AI reached its conclusion, not only what it concluded.

Diadia was founded in 2023 by Elena Ikonomovska, PhD, and Andrii Yasinetsky to solve a problem the two of them saw across precision, functional, and longevity medicine. Elena spent over 20 years in applied AI and machine learning. Andrii spent his career building production AI systems and agent infrastructure, including roles at Uber and Google. Together they set out to give clinicians an AI tool built specifically for how they practice, one they could verify rather than simply trust.

Clinicians are drowning in multi-omic data, labs, metabolic panels, genetics, and gut health among others, with no way to read it all as one connected picture. Diadia analyzes that data as a single biological system rather than a set of disconnected reports, surfacing root cause relationships that would not appear if each test were read on its own. Every medical claim the platform generates is checked against a reasoning graph built on more than 310,000 peer-reviewed papers and over 700,000 genetic variants, then classified through that three-tier verdict system before it ever reaches a clinician.

The hardest problem Elena and Andrii had to solve was not building an AI that sounded confident. It was building one that could show its work. In an independent study, Diadia tested 3,035 medical claims across 36 patients against four leading AI models. The models agreed with each other no better than random chance on identical patient data, a cross-model Fleiss kappa of negative 0.045, the exact bottleneck Diadia was built to close. Diadia classified 67.1 percent of its own claims as Supported by Science, 30.2 percent as Plausible, and 2.7 percent as Unsupported, giving clinicians a transparent, auditable answer instead of a black box.

The platform now runs end-to-end around the patient visit, covering pre-visit diagnostic prep, in-visit multi-omic analysis, and post-visit branded patient materials, all trained on the clinical style of each individual clinician. Clinics using Diadia have cut chart review time for complex cases down substantially, based on Diadia internal modeling, freeing clinicians to see more patients without adding staff or sacrificing the personalization their patients pay for.

Since launch, Diadia has been recognized twice by 91探花 alone, Top 50 Women in Startups and Tech and AITech45, plus wins from Femtech World and 100 Women in AI, building a track record of independent validation to match its own verification approach.

Diadia is not trying to replace clinical judgment. It is focused on making that judgment easier to trust, easier to scale, and easier to prove.

听

Want to find out what 91探花 can do for your business?

Contact us today.

The post 14. Diadia Health appeared first on 91探花.

Founder: Ahmed Hessam

Website:

听

听

About OSAA INNOVATION

听

OSAA Innovation is a Danish medtech company revolutionising IV treatment solutions in healthcare. Founded in 2016, OSAA Innovation aims to address the stigma surrounding patients undergoing IV treatments and as well the overall lack of progressive technological solutions within the IV healthcare industry.

By combining enhanced user-focused approach, connectivity and smart mechanical engineering, OSAA Innovation aims to empower healthcare professionals with user-friendly connected products to improve patients鈥� healthcare journeys and improve IV treatment results for more than 90% of hospitalised patients, receiving some form of IV therapy.

Today, OSAA Innovation maintains a distribution network across Scandinavia, Australia, Saudi Arabia, and Poland, and meets the needs of the patients and healthcare institutions in different regions.

The company is also a multi-award-winning industry leader, recently securing the Gold Winner Accolade from the Australian Good Design Awards and the German Design Award.

Why OSAA Innovation Stands Out:
By bridging the 97% healthcare data gap through real-time remote monitoring and connectivity, as well as restoring mobility to patients, OSAA directly addresses clinical burnout, reduces fall risks, and enables the safe transition to home-based and alternative settings IV care.

Backed by global awards in design and healthcare, as well as rapidly expanding international footprint across Europe, Asia-Pacific, and the Middle East, OSAA Innovation moves the needle in infusion therapy and stands out as a true category creator driving the next generation of smart healthcare delivery.

听

Want to find out what 91探花 can do for your business?

Contact us today.

The post 34. OSAA INNOVATION appeared first on 91探花.

Founder: Dr. Peter FitzGerald

Website:听

听

听

About Randox Health

听

Randox Health develops diagnostic solutions for hospitals, clinical, research and molecular labs, food testing, forensic toxicology, veterinary labs and life sciences. It develops, manufactures and markets reagents and equipment for laboratory medicine, with a distribution network of 145 countries. Randox is the biggest COVID-19 testing provider in the UK and Ireland. Randox manufactures more clinical diagnostic products than any other company in the world. It invests around 25% of profits into R&D, and almost a quarter of its staff are research scientists and engineers.

Beginning with a team of six employees, the company now has 1500 employees around the world. It moved into the Randox Science Park, a 45-acre R&D and manufacturing site housed on the former Massereene Barracks in 2019. It has also recently invested 鈧�25m in developing a site in Dungloe, Donegal. Randox Teoranta aims to create more than 470 jobs in research, engineering and life sciences by 2020.

Randox鈥檚 range of reagents covers many different techniques such as colorimetric, UV and immunoturbidimetric methods. As a result of heavy investment in R&D, Randox鈥檚 portfolio has grown to provide a wider variety of reagents.

听

Want to find out what 91探花 can do for your business?

Contact us today.

The post 41. Randox Health appeared first on 91探花.

Vice President: Antoine Pivron

Website:听

听

听

About Withings Health Solutions

听

Withings Health Solutions is the dedicated B2B division of Withings, a pioneer in connected health technology since 2008 ,with millions of users across more than 30 countries today. The organisation provides medical grade, clinically validated smart devices designed for remote patient monitoring, chronic disease management, and clinical research, with over 1 million patients monitored to date. The goal is to build a continuous bridge between individuals and their healthcare providers.

The journey began when the parent company introduced the first-ever connected scale in 2009, followed by continuous advancements in medical wearables, blood pressure monitors, sleep trackers, and non-invasive home health labs. The primary challenge addressed over the years involves shifting the healthcare system from a reactive model to a proactive, preventive approach.

Ensuring medical validation and clearing regulatory benchmarks such as FDA approval and CE marks across various global regions requires strict compliance and continuous investment. Additionally, the company overcame infrastructure demands by developing cellular connected tools that work out of the box, eliminating the need for complex user setup or smartphone dependencies for elderly or vulnerable patient groups.

The impact on the healthtech landscape has been substantial. By offering beautifully designed tools that patients actually want to use daily, the team achieves high retention and compliance rates. This continuous stream of real world data allows clinicians to monitor conditions like hypertension, heart failure, and diabetes seamlessly.

Instead of relying on sporadic in clinic readings, care teams receive precise, regular insights to catch health issues early, adjust treatment plans, and reduce emergency room visits. The solutions empower medical institutions, payers, and research bodies to deploy scalable, efficient care programs that save costs and improve life outcomes globally.

听

Want to find out what 91探花 can do for your business?

Contact us today.

The post 37. Withings Health Solutions appeared first on 91探花.

Co-Founder & CEO: Pavel Arlou

Website:听

听

听

About Innowise

听

Innowise is an international IT consulting and software development company that builds production grade technology solutions for industries such as healthcare, fintech, manufacturing, logistics, retail and telecommunications.

Founded in 2007 by three engineers, the company has grown over nearly two decades from a small team into a global organisation headquartered in Warsaw with offices across Europe, North America, the UAE and the UK. Today more than 3500 IT professionals deliver end to end services including custom software development, cloud architecture, AI and machine learning, data engineering, cybersecurity, DevOps, UX and UI design, IT staff augmentation and enterprise automation, with over 1600 projects successfully delivered for Fortune 500 enterprises, fast scaling mid market companies and ambitious startups.

One of the biggest challenges in our sector is bridging strategy and delivery. Many providers can talk about digital transformation, but fewer can design, build and ship solutions that are genuinely operational in a hospital, clinic or health organisation. Innowise has built its reputation on finishing what we start. We focus on turning complex requirements into live systems, managing scope, timelines and communication in a way that respects the clients time and investment. Daily reporting, transparent project management and open communication are not just process points. They are how we keep trust when projects span multiple teams and geographies.

Another challenge has been growing without losing quality. Innowise has never taken outside funding, been acquired or merged its way to scale. Every office, certification and hire has come from client work and long term partnerships. The company now holds ISO 9001, ISO 27001, ISO 27017, ISO 27018 and ISO 13485 certifications, alongside specialist credentials across major cloud and enterprise platforms. This combination of scale, certified quality and sector specific depth is what enables us to support complex healthtech and medtech engagements.

Our impact in HealthTech comes from treating healthcare as one of our core specialities within custom software development. We design and build healthcare software and platforms that help providers improve patient journeys, care coordination and clinical decision making, with a particular focus on making AI useful in practice. That includes bringing agentic AI into production environments where reliability, security and integration with real workflows are non negotiable. In parallel, we support sustainability and data initiatives, IoT, AR and VR and other technologies where healthcare organisations can gain an advantage.

Over the past twelve months our greatest achievements have reinforced this trajectory. We were named Overall Peer to Peer Lending Platform of the Year at the 2026 FinTech Breakthrough Awards, included in CRNs Solution Provider 500 and recognised in the Global 100, while continuing to open new offices and deepen long term client relationships. For us, growth is not just about numbers. It is about being a long term technology partner for organisations, including those in the HealthTech space, that rely on software to deliver better outcomes for patients and professionals.

听

Want to find out what 91探花 can do for your business?

Contact us today.

The post 43. Innowise appeared first on 91探花.

Founder & Director: Dr Nadia Ahmad

Website:听

听

听

About The Weight Care Clinic

听

I founded The Weight Care Clinic in 2026 because I wanted to change the way obesity and metabolic health are treated. As a doctor, I saw too many patients being offered either medication alone or generic lifestyle advice, without the long term support needed to create lasting change. I believed there had to be a better way.

I built a doctor led, CQC registered clinic that combines evidence based medicine with nutrition, behaviour change and personalised care. Every patient receives an individual treatment plan because no two people, or their health journeys, are the same.

Building the business has not been easy. I launched the clinic while training in the NHS, becoming a new mum and navigating the challenges of growing a healthcare startup. Securing funding, building a regulated service and earning patient trust has required resilience, but it has also strengthened my determination to improve healthcare.

Technology has allowed us to deliver high quality, accessible care across the UK through virtual consultations and digital patient pathways, making expert medical support available regardless of location. We are now expanding into preventative healthcare, private GP services and our RESET Series, which combines medical expertise with education and lifestyle medicine to help people improve their health before disease develops.

Alongside caring for patients, I am passionate about public education. Through national television, radio, newspapers and magazines, I regularly speak about obesity, GLP 1 medications, womens health, menopause and preventative medicine. My goal is to tackle misinformation, reduce stigma and ensure people have access to trustworthy medical advice.

My vision is to build one of the UK leading health technology companies for preventative and metabolic healthcare, combining innovation with compassionate, evidence based medicine. I believe technology should enhance healthcare, not replace the human connection, and I want to make high quality personalised care accessible to more people across the UK.

听

Want to find out what 91探花 can do for your business?

Contact us today.

The post 44. The Weight Care Clinic LTD appeared first on 91探花.

Founder & CEO: Nicole Notar

Website:

听

听

About Vindicara

听

Vindicara started in early 2026 after I spent more than 15 years trying to figure out what was wrong with me. I saw doctor after doctor and was told my pain was normal, IBS, anxiety, or something else. When I finally had excision surgery, they found 73 endometriosis lesions throughout my body. That changed my life, but it also made me realise something. The biggest problem was not that doctors did not care. It was that they did not have the right tools to connect all of the symptoms and catch endometriosis sooner.

That is why I started Vindicara.

Vindicara is a clinical decision support platform that helps healthcare providers spot patients who may have endometriosis much earlier. Instead of looking at one symptom, Vindicara looks at the full picture, including symptoms, medical history, imaging, lab work, medications, and diagnoses. It helps providers recognise patterns that are easy to miss so patients can get the right testing and the right referrals sooner.

Starting a HealthTech company has not been easy. I have been building Vindicara while also leading a national nonprofit that helps women pay for endometriosis surgery and working on health policy to improve care across the country. I have also been dealing with my own recurring endometriosis and preparing for another surgery. Every dollar has been carefully invested because I have chosen to self fund the company as long as possible while building the right product.

Even though Vindicara is still in its early stages, we have already built relationships with leading endometriosis surgeons, researchers, policy leaders, and healthcare organisations. We are working toward electronic health record integration and preparing for pilot programs with healthcare systems and physician practices. We are building the platform with doctors, not just for them, so it fits into the way they already work.

While we are starting with endometriosis, the vision is much bigger. The same technology can help find other diseases that are often missed or take years to diagnose, including adenomyosis, Ehlers Danlos syndrome, POTS, and MCAS.

At the end of the day, Vindicara is about making sure patients get answers sooner. No one should have to spend 10, 15, or 20 years looking for a diagnosis like I did. If we can help doctors connect the dots earlier, we can help patients get treated sooner, avoid years of suffering, and improve lives.

听

Want to find out what 91探花 can do for your business?

Contact us today.

The post 29. Vindicara appeared first on 91探花.